{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:16:01Z","timestamp":1783091761154,"version":"3.54.6"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.parkreldis.2020.10.013","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T03:32:37Z","timestamp":1601955157000},"page":"199-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Insulin resistance, diabetes and Parkinson's disease: The match continues"],"prefix":"10.1016","volume":"80","author":[{"given":"Anna","family":"Delamarre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rigalleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassilios G.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.parkreldis.2020.10.013_bib1","doi-asserted-by":"crossref","first-page":"e3549","DOI":"10.1097\/MD.0000000000003549","article-title":"Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine (Baltim.)"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.10.013_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085781","article-title":"Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies","volume":"9","author":"Lu","year":"2014","journal-title":"PloS One"},{"issue":"19","key":"10.1016\/j.parkreldis.2020.10.013_bib3","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and Parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.10.013_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jns.2017.04.010","article-title":"Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson's disease","volume":"377","author":"Ong","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.10.013_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the de novo Parkinson cohort (DeNoPa)","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.10.013_bib6","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study","volume":"31","author":"Svenningsson","year":"2016","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2020.10.013_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224236","article-title":"Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: an exploratory meta-analysis","volume":"14","author":"Zhu","year":"2019","journal-title":"PloS One"},{"issue":"10103","key":"10.1016\/j.parkreldis.2020.10.013_bib8","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.parkreldis.2020.10.013_bib9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.parkreldis.2015.07.017","article-title":"Prospective study on the components of metabolic syndrome and the incidence of Parkinson's disease","volume":"21","author":"Saaksjarvi","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.10.013_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/JPD-181305","article-title":"High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson's disease","volume":"8","author":"Hogg","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.10.013_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2020.08.018","article-title":"Peripheral insulin and amylin levels in Parkinson\u2019s disease","volume":"79","author":"S\u00e1nchez-G\u00f3mez","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.10.013_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13340-018-0347-1","article-title":"IAPP\/amylin and beta-cell failure: implication of the risk factors of type 2 diabetes","volume":"9","author":"Kanatsuka","year":"2018","journal-title":"Diabetol Int"},{"issue":"4","key":"10.1016\/j.parkreldis.2020.10.013_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23956","article-title":"Amylin deposition in the brain: a second amyloid in Alzheimer disease?","volume":"74","author":"Jackson","year":"2013","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.10.013_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ana.25570","article-title":"Amylin as a potential link between type 2 diabetes and alzheimer disease","volume":"86","author":"Martinez-Valbuena","year":"2019","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.10.013_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.9826","article-title":"Association of plasma amylin concentration with alzheimer disease and brain structure in older adults","volume":"2","author":"Zhu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.10.013_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218561","article-title":"Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease","volume":"14","author":"Schultz","year":"2019","journal-title":"PloS One"},{"issue":"44","key":"10.1016\/j.parkreldis.2020.10.013_bib16","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1073\/pnas.1610371113","article-title":"Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease","volume":"113","author":"Horvath","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.10.013_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00401-018-1832-0","article-title":"Interaction of amyloidogenic proteins in pancreatic beta cells from subjects with synucleinopathies","volume":"135","author":"Martinez-Valbuena","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.10.013_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00500385","article-title":"Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients","volume":"34","author":"Sanke","year":"1991","journal-title":"Diabetologia"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020307884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020307884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:21:19Z","timestamp":1761178879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020307884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":19,"alternative-id":["S1353802020307884"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.10.013","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin resistance, diabetes and Parkinson's disease: The match continues","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}